Adaptive microcombs for innovative connectivity in datacenter applications and optical clocks
Amica aims to revolutionize datacentre interconnects by developing a scalable microcomb technology for multi-wavelength laser sources, targeting petabit-per-second speeds and efficient mass production.
Projectdetails
Introduction
The rampant growth of ICT applications, such as AI, is moving an increasing amount of computing resources to datacentres. Datacentres are responsible for approximately three quarters of the internet protocol data in the world. The continuous increase in data traffic and bandwidth demands are challenging the status quo of the datacentre interconnect architecture.
Challenge
The outstanding challenge for the next decade is finding scalable and efficient solutions to enable the bandwidth density that will be needed.
Enabling Technology
Co-packaged optics (CPO) is the enabling technology to drive this shift in the computational efficiency paradigm. It is projected to have the largest forecasted CAGR in silicon photonics from 2022 to 2026, with potential multi-billion dollar revenues beyond 2030.
Key Features of CPO
CPO is based on decreasing the distance of power-hungry electrical interfaces by co-integrating optoelectronic modules on the same interposers.
Requirements for Optical Edge Bandwidth Density
In order to drive the scaling in optical edge bandwidth density, multi-wavelength laser sources for dense wavelength division multiplexing will be needed. However, state-of-the-art commercial solutions face fundamental scaling issues.
Project Overview
Amica builds upon a breakthrough wafer-scalable, super-efficient microcomb technology to realize critical demonstrators in WDM CPO. The project aims at petabit-per-second aggregate speeds in a mass-manufacturable platform with an unprecedented combination of:
- Channel count
- Efficiency
- Line spacing
- Power per line
Consortium
The consortium brings a synergetic effort among:
- An industrial leader in datacentre interconnects and high-performance computing
- Academic partners with complementary expertise in integrated photonics
- An emerging startup that owns the intellectual property rights for commercialization
The team is complemented with an innovation office to lead the tech-to-market transition, and two associated partners who will help test the technology for emerging markets beyond telecom.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.499.340 |
Totale projectbegroting | € 2.499.340 |
Tijdlijn
Startdatum | 1-8-2024 |
Einddatum | 31-7-2027 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- CHALMERS TEKNISKA HOGSKOLA ABpenvoerder
- MELLANOX TECHNOLOGIES LTD - MLNX
- UNIVERSITEIT GENT
- R INNOVATION AB
- ILOOMINA AB
- MENLO SYSTEMS GMBH
- NKT PHOTONICS A/S
Land(en)
Vergelijkbare projecten binnen EIC Transition
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Targeting cardiac fibrosis with next generation RNA therapeuticsFIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness. | EIC Transition | € 2.499.482 | 2022 | Details |
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationSThe NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring. | EIC Transition | € 2.497.750 | 2022 | Details |
Predictive REagent-Antibody Replacement Technology stage 2-TranslationPRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment. | EIC Transition | € 800.000 | 2022 | Details |
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stageDeveloping a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships. | EIC Transition | € 2.499.810 | 2022 | Details |
Targeting cardiac fibrosis with next generation RNA therapeutics
FIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness.
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationS
The NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring.
Predictive REagent-Antibody Replacement Technology stage 2-Translation
PRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment.
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stage
Developing a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Photonic Integrated Circuits For Access System in TelecomPICadvanced aims to develop a novel Photonic Integrated Circuit design for Optical Network Units, enabling 10Gbps broadband with minimal upgrades, reduced costs, and lower environmental impact. | EIC Accelerator | € 2.444.378 | 2024 | Details |
Active Hybrid Photonic Integrated Circuits for Ultra-Efficient Electro-Optic Conversion and Signal ProcessingATHENS aims to revolutionize electro-optic conversion in photonic integrated circuits by developing advanced materials and integration techniques for enhanced performance in communications and quantum technologies. | ERC SyG | € 13.999.999 | 2025 | Details |
NEWPhotonics: The Future of Data Center TechnologiesNEWPhotonics develops efficient all-optical chip solutions to reduce energy consumption and costs in hyperscale data centers, enhancing speed, reliability, and scalability. | EIC Accelerator | € 2.499.742 | 2022 | Details |
FODAMED - Disruptief fotonisch platform voor datacom en medische diagnostiekHet FODAMED-project ontwikkelt een nieuw productieplatform voor fotonica, gericht op hoge snelheid optische communicatie en medische toepassingen, om te voldoen aan de groeiende databehoefte. | MIT R&D Samenwerking | € 237.941 | 2017 | Details |
Photonic Integrated Circuits For Access System in Telecom
PICadvanced aims to develop a novel Photonic Integrated Circuit design for Optical Network Units, enabling 10Gbps broadband with minimal upgrades, reduced costs, and lower environmental impact.
Active Hybrid Photonic Integrated Circuits for Ultra-Efficient Electro-Optic Conversion and Signal Processing
ATHENS aims to revolutionize electro-optic conversion in photonic integrated circuits by developing advanced materials and integration techniques for enhanced performance in communications and quantum technologies.
NEWPhotonics: The Future of Data Center Technologies
NEWPhotonics develops efficient all-optical chip solutions to reduce energy consumption and costs in hyperscale data centers, enhancing speed, reliability, and scalability.
FODAMED - Disruptief fotonisch platform voor datacom en medische diagnostiek
Het FODAMED-project ontwikkelt een nieuw productieplatform voor fotonica, gericht op hoge snelheid optische communicatie en medische toepassingen, om te voldoen aan de groeiende databehoefte.